Next Article in Journal
Merkel Cell Carcinoma in Immunosuppressed Patients
Next Article in Special Issue
Collagenolytic Matrix Metalloproteinases in Chronic Obstructive Lung Disease and Cancer
Previous Article in Journal
Merkel Cell Polyomavirus: Molecular Insights into the Most Recently Discovered Human Tumour Virus
Previous Article in Special Issue
Fibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinase (TIMPs)
Article Menu

Export Article

Open AccessReview
Cancers 2014, 6(3), 1298-1327;

Roles of Matrix Metalloproteinases and Their Natural Inhibitors in Prostate Cancer Progression

Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
Author to whom correspondence should be addressed.
Received: 4 April 2014 / Revised: 31 May 2014 / Accepted: 9 June 2014 / Published: 27 June 2014
(This article belongs to the Special Issue Matrix Metalloproteinases in Cancer Progress)
Full-Text   |   PDF [721 KB, uploaded 27 June 2014]   |  


Matrix metalloproteinases (MMPs), a group of zinc-dependent endopeptidases involved in the degradation of the extracellular matrix, play an important role in tissue remodeling associated with various physiological processes such as morphogenesis, angiogenesis, and tissue repair, as well as pathological processes including cirrhosis, arthritis and cancer. The MMPs are well established as mediators of tumor invasion and metastasis by breaking down connective tissue barriers. Although there has been a vast amount of literature on the role of MMPs in invasion, metastasis and angiogenesis of various cancers, the role of these endopeptidases in prostate cancer progression has not been systematically reviewed. This overview summarizes findings on the tissue and blood expression of MMPs, their function, regulation and prognostic implication in human prostate cancer, with a focus on MMP-2, -7, -9, MT1-MMP and tissue inhibitor of metalloproteinase 1 (TIMP-1). This review also summarizes the efficacy and failure of early-generation matrix metalloproteinase inhibitors (MMPIs) in the treatment of metastatic prostate cancer and highlights the lessons and challenges for next generation MMPIs. View Full-Text
Keywords: MMP; TIMP; prostate cancer MMP; TIMP; prostate cancer

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Gong, Y.; Chippada-Venkata, U.D.; Oh, W.K. Roles of Matrix Metalloproteinases and Their Natural Inhibitors in Prostate Cancer Progression. Cancers 2014, 6, 1298-1327.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top